Alzheimer’s Therapeutics Market size is anticipated to reach USD 6.4 billion in 2024. Alzheimer’s disease is a progressive, non-reversible, and neurodegenerative disorder. Alzheimer is caused due to abnormal functioning of brain cells. It is the most common form of dementia. In simple words, it is a biological disease marked by physical changes in the brain and most remarkably build-up of small protein clumps called “Tangles” and “Plaques” that lead to the death of nerve cells.
The
factors that propel the growth of the Alzheimer’s therapeutics market include
well-developed healthcare infrastructure, high consciousness levels, increase
in incidence of neurodegenerative diseases, growing aged population, and
increasing R&D investment. On the other hand, there are factors that may
hamper the growth of the market including lack of transparent reimbursements,
high cost of treatment and diagnosis in the later stage, typically owing to
delayed appearance of symptoms.
Request Sample Copy of This Market Research @
https://www.millioninsights.com/industry-reports/alzheimers-therapeutics-market/request-sample
The
new product launches and research collaborations are some of the key strategies
adopted by the top industry players. For instance, Actavis plc in collaboration
with Adamas Pharmaceuticals Inc. lately publicized the US FDA approval of
Namzaric, a fixed-dose combination of donepezil and memantine. The drug is
likely to be launched in the first half of year 2015. Additionally, in Jan
2015, Johnson & Johnson signed a research deal with a Swiss biotech firm AC
Immune, to change anti-tau Alzheimer's vaccines.
Alzheimer’s
therapeutics industry is anticipated to expand at a significant CAGR in the
upcoming period as the scope, product types, and its applications are
increasing across the globe. Alzheimer’s therapeutics market could be explored
by therapeutic type, application and geography. The market could be explored by
therapeutic type as N-methyl-D-aspartate (NMDA) receptor antagonist and
Cholinesterase Inhibitors. The “Cholinesterase Inhibitors” segment led the
Alzheimer’s therapeutics industry in 2016 and is anticipated to maintain its
dominance by 2024. The key applications that could be explored in the
Alzheimer’s therapeutics market include Moderate to severe Stages, and Early to
Moderate Stages.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/alzheimers-therapeutics-market
North
America accounted for the major share of the Alzheimer’s therapeutics industry
in 2016 and will continue to lead in the forecast period. The factors that
could be attributed to the growth include increasing prevalence of Alzheimer’s
disease, growing aged population, extensive technological advancements in the
region, high awareness levels, and strong healthcare infrastructure. North
America is likely to be followed by Europe.
Comments
Post a Comment